AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00536601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV
Study NCT00536601 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00536601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo ASCT
Study NCT00536601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: Undergo tandem ASCT
Study NCT01327885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m^2 intravenous
Description: Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
Study NCT01327885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
Description: Administration of dacarbazine at a dose of 850 mg/m\^2, or 1,000 mg/m\^2, or 1,200 mg/m\^2 selected by the Principal Investigator \[PI\] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
Study NCT02990091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
Study NCT02990091 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower seed oil
Description: Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
Study NCT04319380 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01
Description: One booster dose of RTSS/AS01 (June) in year 1 and 2.
Study NCT04319380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC placebo
Description: Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
Study NCT03277638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab at 7 days prior
Description: Pembrolizumab injections 7 days before surgery
Study NCT03277638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab at 14 days post
Description: Pembrolizumab injections 14 days after surgery
Study NCT03277638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab at 35 days post
Description: Pembrolizumab injections 35 days after surgery
Study NCT03277638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermotherapy
Description: surgical procedure to heat hard to reach tumors with a laser beam
Study NCT02428556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facts only
Description: Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
Study NCT02428556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: promising language
Description: Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)
Study NCT02428556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakthrough only
Description: Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
Study NCT02428556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breakthrough with may warning
Description: Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials
Study NCT02428556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breakthrough with is warning
Description: Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials.
Study NCT00309751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg QD
Study NCT00309751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20 mg
Study NCT01502813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline, Omega-3 Fatty Acids and Creatine
Description: Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
Study NCT02613403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
Study NCT02613403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
Study NCT00733174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: tablet
Study NCT00733174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02807857 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Description: Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
Study NCT02115659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptolide-Containing Formulation
Description: Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
Study NCT02115659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
Study NCT00778856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand transplantation
Description: allotransplantation of deceased donor composite tissue (hand and forearm)
Study NCT02493166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task cost (cognitive-motor interference)
Description: comparing single versus dual task performance (on both motor and cognitive task)
Study NCT04536766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sleep Health Education
Description: The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.
Study NCT04536766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beds for Kids Standard Program
Description: The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
Study NCT03918252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
Study NCT03918252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection
Description: Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
Study NCT03440645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-oriented primary cardiovascular prevention
Description: An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
Study NCT02440438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
Study NCT01147471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: operative rib fixation
Description: Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
Study NCT01147471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative rib fixation surgery
Study NCT00056654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: 45 mg Intramuscular injection 6 month depot formulation
Study NCT02667366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tel-PT
Study NCT02667366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU and text messages
Study NCT01463475 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone marrow aspirate
Description: A single bone marrow aspirate procedure is planned.
Study NCT02067819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Oral Orthotic Treatment
Description: Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
Study NCT02067819 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Orthotic Treatment
Description: After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
Study NCT01540305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
Study NCT01540305 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
Study NCT03715985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVAX-01-CAF09b
Description: The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
Study NCT03611088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Position.
Description: The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
Study NCT04561089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVIDSeq Test
Description: The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
Study NCT03705663 — intervention group
Intervention type: BEHAVIORAL
Intervention: PrEP initiation
Description: Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
Study NCT00738400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
Study NCT00738400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
Study NCT03153306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin
Description: Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)
Study NCT03987698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 injection
Study NCT03987698 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHR-1210
Description: SHR-1210 injection
Study NCT03987698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK cells
Description: CIK cells injection
Study NCT03142490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
Study NCT03142490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
Study NCT03142490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
Study NCT01903109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cevimeline
Study NCT03800368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Indoor cycling exercise intervention
Study NCT03800368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-exercise
Description: Psycho-education
Study NCT01094106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,75%
Description: Postoperative wound infusion 2 ml/ h/ 48h
Study NCT01094106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: Postoperative wound infusion 2 ml/h/48h
Study NCT00237224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT02993926 — intervention group
Intervention type: DRUG
Intervention: Enantone
Description: Enantone suspension for injection
Study NCT02993926 — intervention group
Intervention type: DRUG
Intervention: GnRH agonist
Description: A non-Enantone GnRH agonist
Study NCT00452114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-Exsufflator Cough Assist Device
Study NCT00452114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Flutter Valve Device
Description: Active Comparator
Study NCT02298998 — intervention group
Intervention type: OTHER
Intervention: Intervention
Description: Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
Study NCT02298998 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
Study NCT06667648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cupping session
Description: Each cupping session takes about 30-40 min and can be conducted in five steps. The first step includes primary suction. In this phase, the therapist allocates specific points or areas for cupping and disinfects the area, which located at the upper back (opposite to C7), Para spinal and below scapula. A cup with a suitable size is placed on the selected site and sucked the air inside the cup by manual suction. Then the cup was applied to the skin and left for a period of 3 to 5 min. The second step is about puncturing. Puncturing with a needle to get out of blood the third step is about suction and bloodletting. The cup is placed back on the skin using the similar procedure described above for 3 to 5 min. The fourth step includes the removal of the cup, followed by the fifth step which includes dressing the area after cleaning and disinfecting with FDA-approved skin disinfectant.
Study NCT03972345 — intervention group
Intervention type: DRUG
Intervention: Norditropin® FlexPro®
Description: Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
Study NCT02511184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
Study NCT02511184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
Study NCT00840554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based physical therapy program.
Description: All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
Study NCT00840554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program.
Description: In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
Study NCT03861715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: live birth rate
Description: The blastulation rate and live birth rate according to the protocol of COS
Study NCT04337606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
Study NCT04337606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
Study NCT04337606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
Study NCT03627533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
Study NCT03627533 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
Study NCT02694874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
Study NCT02694874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo control